We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesInozyme Pharma Inc

Inozyme Pharma Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2025-08-04T13:01:41.357764Z
Market Cap
87.37M

Momentum Score

…

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
1.32
Low
7.79
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.33
ROE
-79.42%
Net Debt
12.00M
ROCE
-37.29%
Diluted EPS TTM
-1.55

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -67.06M -56.62M -56.42M -19.72M -6.96M
Net income -65.45M -56.41M -55.84M -18.62M -6.96M
Selling general administrative 20.83M 18.93M 10.55M 4.59M 3.49M
Reconciled depreciation 0.74M 0.67M 0.22M 0.08M 0.03M
Ebit -69.42M -56.65M -57.26M -20.81M -11.59M
Ebitda -68.67M -55.97M -57.04M -20.72M -11.57M
Depreciation and amortization 0.74M 0.67M 0.22M 0.08M 0.03M
Non operating income net other 1.42M 0.02M 0.61M - -
Operating income -68.67M -56.65M -57.04M -20.81M -11.59M
Other operating expenses 68.67M 56.65M 57.04M 20.81M 11.59M
Interest expense -1.61M 0.02M 0.37M 0.00M 0.00M
Interest income 1.93M 0.21M 0.37M 1.11M 0.28M
Net interest income 1.93M 0.21M 0.37M 1.11M 0.28M
Income tax expense -1.61M -0.21M -0.59M -1.11M 4.63M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 68.67M 56.65M 57.04M 20.81M 11.59M
Total other income expense net 1.61M 0.02M 0.62M 1.08M 4.34M
Net income from continuing ops -67.26M -56.62M -56.42M -19.72M -6.96M
Net income applicable to common shares -67.06M -56.62M -56.42M -19.72M -6.96M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 200.85M 139.19M 123.54M 169.36M 47.94M
Other current assets 7.28M 3.53M 3.54M 3.28M 0.22M
Total liab 60.37M 20.80M 14.27M 11.26M 81.16M
Total stockholder equity 140.48M 118.59M 109.27M 158.10M -33.22M
Deferred long term liab - - - - 0.06M
Other current liab 12.61M 7.54M 8.51M 6.90M 2.33M
Common stock 0.01M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.01M 0.00M 0.00M 0.00M 0.00M
Retained earnings -285.93M -214.76M -147.70M -91.08M -34.65M
Other liab - - - 1.29M -
Other assets - - 3.76M 15.74M 0.19M
Cash 34.59M 32.91M 23.32M 159.90M 31.61M
Total current liabilities 14.69M 14.71M 11.63M 9.97M 3.24M
Current deferred revenue - 3.81M - - -
Net debt 12.00M -26.14M -19.95M -159.90M -31.61M
Short term debt 0.91M 0.82M 0.73M - -
Short long term debt total 46.59M 6.78M 3.37M - -
Other stockholder equity 426.36M 333.56M 133.41M 79.81M 1.43M
Property plant equipment - 2.02M 4.44M 2.65M 0.30M
Total current assets 196.25M 131.39M 115.34M 150.98M 47.46M
Long term investments - - 0.00M 12.20M -
Net tangible assets - 118.39M 109.27M 158.10M -33.22M
Short term investments 154.00M 94.95M 88.48M 119.66M 15.53M
Net receivables 0.39M 0.12M 0.06M 0.15M 0.10M
Long term debt 44.77M 4.14M - - -
Inventory - -0.12M -0.06M -12.35M -
Accounts payable 1.17M 2.54M 2.39M 3.07M 0.90M
Accumulated other comprehensive income 0.04M -0.20M 0.02M 0.00M 0.01M
Common stock total equity - 0.00M 0.00M 0.00M -
Retained earnings total equity - -214.76M -147.70M -91.08M -
Non currrent assets other 1.69M 4.16M 3.76M 3.54M 0.19M
Non current assets total 4.60M 7.80M 8.20M 18.38M 0.48M
Capital lease obligations 1.82M 2.64M 3.37M - -
Long term debt total - 4.14M - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -4.99M 43.19M -117.18M -8.39M 9.01M
Change to liabilities 3.13M -0.68M 2.10M -0.08M 0.80M
Total cashflows from investing activities -5.40M 42.80M -117.18M -8.39M 9.01M
Net borrowings 4.05M - - - -
Total cash from financing activities 72.79M 0.61M 149.81M 22.97M 31.95M
Change to operating activities - 0.76M -2.21M 0.68M 0.63M
Net income -67.06M -56.62M -56.42M -19.72M -6.96M
Change in cash 9.60M -4.72M -3.34M -4.23M 31.51M
Begin period cash flow 23.67M 28.39M 31.73M 35.97M 4.45M
End period cash flow 33.27M 23.67M 28.39M 31.73M 35.97M
Total cash from operating activities -57.76M -48.15M -35.97M -18.81M -9.44M
Issuance of capital stock 56.14M 0.00M 149.61M 22.90M 31.95M
Depreciation 0.74M 0.67M 0.22M 0.08M 0.03M
Other cashflows from investing activities - - - -8.25M 9.27M
Sale purchase of stock 0.09M 0.61M 149.81M 22.97M 31.95M
Other cashflows from financing activities 16.56M 0.61M 33.84M -8.39M 31.95M
Change to netincome 7.69M 7.71M 20.34M 0.23M -3.93M
Capital expenditures 0.41M 0.40M 0.57M 0.14M 0.26M
Cash flows other operating -0.69M -0.73M -6.14M - -
Exchange rate changes - 0.02M - - -
Cash and cash equivalents changes 9.62M -4.72M -3.34M - -
Change in working capital 2.01M 0.09M -0.11M 0.60M 1.43M
Stock based compensation 7.67M 7.16M 2.31M 0.30M 0.44M
Other non cash items -1.13M 0.38M 18.04M -0.07M -4.37M
Free cash flow -58.17M -48.55M -36.54M -18.95M -9.70M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Inozyme Pharma Inc

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

321 Summer Street, Boston, MA, United States, 02210

857 330 4340

https://www.inozyme.com

59

Name Title Year Born
Mr. Axel Bolte M.B.A., M.Sc. Co-Founder, Pres, CEO & Director 1972
Mr. Henric Bjorn Bjarke Sr. VP & COO 1967
Dr. Demetrios Braddock M.D., Ph.D. Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer NA
Mr. Sanjay S. Subramanian M.B.A., M.S. CFO & Principal Accounting Officer 1977
Dr. Soojin Kim Ph.D. Sr. VP & Chief Technical Operations Officer NA
Dr. Yves Sabbagh Ph.D. Chairman of Scientific Advisory Board, Sr. VP & Chief Scientific Officer NA
Mr. Stefan Riley Director of Investor Relations NA
Ms. Gayle Gironda Sr. VP & Chief People Officer NA
Dr. David Thompson M.A., M.S., Ph.D. Chief Devel. Officer NA
Mr. Stephen J. Di Palma M.B.A, M.B.A. Consultant 1959

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…